Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1622 1674
This examiner grants 0% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18290478 | NEW SUBSTITUTED QUINOLINES AS FUNGICIDES | Non-Final OA | BASF SE |
| 18453220 | PROCESS OF COUPLING ALDEHYDES | Final Rejection | UOP LLC |
| 18349606 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12V MUTANTS | Non-Final OA | INCYTE CORPORATION |
| 18345547 | THERAPEUTIC COMPOUNDS USEFUL FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF AN HIV VIRUS INFECTION | Non-Final OA | Gilead Sciences, Inc. |
| 18344584 | METHODS OF MANUFACTURE OF R-MDMA | Final Rejection | Mind Medicine, Inc. |
| 18565680 | HYDRATE FORM OF LAZERTINIB MESYLATE, PREPARATION METHOD THEREOF AND USE THEREOF | Non-Final OA | HANGZHOU SOLIPHARMA CO., LTD. |
| 18353717 | DINUCLEAR PLATINUM COMPLEXES FOR OLED APPLICATION | Non-Final OA | Hong Kong Quantum AI Lab Limited |
| 18562865 | Compounds inhibiting the synergistic carsinogenic effect of heavy metals in the presence of other carcinogens for use in the treatment of cancer | Non-Final OA | Cancer Research and Biotechnology AG |
| 18550500 | ANTIVIRAL PRODRUGS OF ETV AND FORMULATIONS THEREOF | Non-Final OA | THE SCRIPPS RESEARCH INSTITUTE |
| 18288435 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETIC RETINOPATHY AND RELATED CONDITIONS | Non-Final OA | Opus Genetics, Inc. |
| 18039229 | NOVEL CAMPTOTHECIN DERIVATIVE, COMPOSITION COMPRISING SAME AND USE THEREOF | Non-Final OA | WIGEN BIOMEDICINE TECHNOLOGY (SHANGHAI) CO., LTD. |
| 18285820 | COMPOUND FOR PREVENTION OR TREATMENT OF KIDNEY DISEASE | Non-Final OA | ONCOCROSS CO.,LTD |
| 18373903 | TREATMENT OF MENTAL DISORDERS | Non-Final OA | GH Research Ireland Limited |
| 18546071 | SMTP-7 DERIVATIVE AND USE THEREOF | Final Rejection | Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
| 18347724 | PHENYL UNSATURATED KETONES AS HUMAN FACTOR XIIIA INHIBITORS FOR TREATMENT OF THROMBOEMBOLIC DISEASES | Non-Final OA | Xavier University of Louisiana |
| 18347479 | CRYSTALLINE FORMS OF A TYK2 INHIBITOR | Non-Final OA | Ventyx Biosciences, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy